Truist Securities Maintains Buy on Allogene Therapeutics, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and maintained a price target of $17.
May 15, 2024 | 6:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating on Allogene Therapeutics and maintained a price target of $17, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a maintained price target of $17 by Truist Securities suggests continued confidence in Allogene Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100